325702-65-6

Upstream product

• 1780-31-0 2,6-dichloro-5-methylpyrimidine 
• 87-25-2 2-ethoxycarbonylaniline 

Downstream Products

• 1042435-05-1 Ethyl 2-[(5-methyl-2-{[3-(4-methyl-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)amino]benzoate 
• 1042435-04-0 ethyl 2-{[5-methyl-2-({3-[2-(4-morpholinyl)ethyl]phenyl}amino)-4-pyrimidinyl]amino}benzoate 
• 1089654-01-2 ethyl 2-[(5-methyl-2-{[6-(4-methyl-1-piperazinyl)-3-pyridinyl]amino}-4-pyrimidinyl)amino]benzoate 
• 1089653-99-5 ethyl 2-((2-chloro-5-methyl-4-pyrimidinyl){[(1.1-dimethylethyl)oxy]carbonyl}amino)benzoate 

Relevant academic research and scientific papers

ANTHRANILAMIDE INHIBITORS OF AURORA KINASE

The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R1, R2, R3, R4, r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.

ANTHRANILAMIDES

The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, and Het are as defined herein. Compounds of the present invention are useful as Aurora kinase inhibitors.